Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab add-on therapy for moderate-to-severe ulcerative colitis
NL-OMON37913Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Feb 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Tralokinumab add-on with Placebo add-on (2 arms). Primary endpoint: Clinical response at week 8. Planned start Feb 2012; status: withdrawn.
02
Drugs
tralokinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON37913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37913.